中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于一心堂药业集团股份有限公司 2023 年年度股东大会的法律意见书 致：一心堂药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）以及中国证券监 督管理委员会颁布的《上市公司股东大会规则（2022年修订）》（以下简称"《股 东大会规则》"）的规定，北京市竞天公诚律师事务所（以下简称"本所"）指派律 师对一心堂药业集团股份有限公司（以下简称"公司"）2023年年度股东大会（以 下简称"本次股东大会"）进行现场见证，并就本次股东大会的有关事宜出具本法 律意见书。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及本法 律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤 勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定的事 实真实、准确、完整，所发表的结论性意见合法、准 ...

一心堂药业集团股份有限公司 投资者调研会议记录 时间：2024 年 5 月 16 日—5 月 17 日 地点：一心堂药业集团股份有限公司总部 召开方式：2023 年年报及 2024 年一季报业绩交流会及 2024 年投资者走进上市 公司活动 投资者：中信证券、中信建投、国联证券、国海证券、华泰证券、长江证券、璟 诚投资、南方基金、华夏久盈资产及长盛基金等 46 家机构投资者 接待人：副总裁兼董事会秘书李正红先生、证券事务代表阴贯香女士 一、企业文化参观 二、座谈交流 问题一：公司客单价、客流量有什么变化？ 答：公司一季度客流量有所上升，客单价略有下降。一季度客流增长带动了 销售收入的增长。 问题二：公司门店拓展情况？ 答：公司坚持核心区域深耕门店高密度布局，重点发展西南、华南地区，同 时兼顾华北地区的门店发展，持续强化在核心发展区域的竞争能力提升。截至 2023 年 12 月 31 日，公司及其全资子公司共拥有直营连锁门店 10,255 家，覆盖 10 个省份及直辖市，云南省内门店数量占比 52.63%，云南省以外区域门店数量 占比 47.37%，较年初增长 4.12%。截止 2024 年一季度末，拥有直营连 ...

Group 1: Investor Relations Activity Overview - The activity involved 46 institutional investors, including major firms like CITIC Securities and Huatai Securities [1] - The event took place from May 16 to May 17, 2024, at the headquarters of Yixintang Pharmaceutical Group [1] - Key personnel included Mr. Li Zhenghong, Vice President and Secretary of the Board, and Ms. Yin Guanxiang, Securities Affairs Representative [1] Group 2: Content of the Investor Relations Activity - The main topics discussed included the 2023 annual report and the Q1 2024 performance exchange meeting [1] - The event was categorized as a specific audience survey and included a company visit [1] - Additional materials provided included records of the investor survey meeting [1]

| --- | --- | --- | |---------------------------------------------------------------------------------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

投资者关系活动记录表 1 证券代码：002727 证券简称：一心堂 一心堂药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------------------|----------------------------------------------------------------| | | | 编号： TG202405-002 | | | □特定对象调研 | □分析师会议 | | | □媒体采访 | ☑ 业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | □其他 （电话会议） | | | 参与单位名称及人员 姓名 | 通过全景网"投资者关系互动平台" 参与" 2023 的全体投资者 | (https://rs.p5w.net) 年度云南辖区上市公司投资者网上集体接待日" | | 时间 | 2024 年 5 月 13 日 | 15:00-16:40 | | | | | | ...

Group 1: Company Performance and Financials - In 2023, the company achieved a revenue of 17.38 billion yuan, with drug retail accounting for 72.66% and convenience goods sales contributing 2% [6] - The net profit in 2023 saw a significant decline, attributed to changes in sales of cold medicines and tax-related issues [6] - The company has consistently received an A-level rating for information disclosure from the Shenzhen Stock Exchange [3] Group 2: Business Strategy and Development - The company focuses on enhancing core competitiveness and improving single-store profitability through service enhancement, category expansion, and supply chain optimization [2] - Future investments will primarily target the expansion of retail drug and health product businesses, with a focus on existing regions and projects such as store expansion and logistics development [4] - The company plans to expand its market share through a combination of self-built stores and acquisitions, with a focus on core areas [5] Group 3: Market Presence and Expansion - As of March 31, 2024, the company operates 10,746 direct chain stores across 10 provinces and municipalities, with 5,455 stores (50.76%) located in Yunnan province [5] - The company aims to strengthen its presence in the Sichuan-Chongqing region while also considering markets in Hainan, Shanxi, Guangxi, and Guizhou [5] - The company maintains a high-density layout in core areas to enhance competitive capabilities [6]

Investment Rating - The report maintains a "Buy" rating for the company, with an "Increase" suggestion based on the expected performance recovery and strategic expansions in key regions [7][22]. Core Insights - The company has accelerated its store expansion, focusing on the Sichuan-Chongqing region while maintaining a strong presence in Yunnan and gradually increasing its market share in South China and North China [1][14]. - In 2023, the company reported a revenue of 17.38 billion yuan, a slight decrease of 0.29% year-on-year, and a significant drop in net profit by 45.60% to 549 million yuan, primarily due to tax-related expenses and a decline in gross margin [8][9][14]. - The first quarter of 2024 showed a recovery with a revenue increase of 14.96% year-on-year, reaching 5.10 billion yuan, and a net profit of 242 million yuan, marking a 1.03% increase [8][14]. Store Expansion and Market Strategy - In 2023, the company opened 1,381 new stores, bringing the total to 10,255 by the end of the year, with a focus on increasing the number of stores outside Yunnan [1][14]. - As of the first quarter of 2024, the total number of stores reached 10,746, with 5,455 in Yunnan and 5,291 outside, indicating a balanced expansion strategy [1][14]. Financial Performance - The company’s gross margin for 2023 was reported at 33.00%, reflecting a slight decline due to increased wholesale proportions and price adjustments in the product catalog [27]. - The forecast for earnings per share (EPS) for 2024-2026 is adjusted to 1.68, 1.95, and 2.28 yuan, respectively, indicating a positive outlook for profitability [22][16]. Diversification and Health Industry Layout - The company is actively diversifying its product categories, focusing on traditional medicine and expanding into the health industry, with sales in the health category reaching 370 million yuan in 2023 [12][14]. - The establishment of a health division aims to address consumer health needs beyond medication, including skincare and functional foods [12][14].

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2024-053 号 一心堂药业集团股份有限公司 关于全资子公司河南鸿翔一心堂药业有限公司对外投资 取得一心堂国控大药房河南连锁有限公司控股权的进展公告 本次投资符合公司业务发展需要及战略规划，但仍然面临市场、经营、管理等各方面不确 定因素带来的风险。为此，公司将采取适当的策略、管理措施加强风险管控，力争获得良好的 投资回报。敬请广大投资者注意投资风险。 第 1 页 共 2 页 一心为民 全心服务 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2024年3月18日召开第六届董事会第七 次会议，审议通过《关于全资子公司河南鸿翔一心堂药业有限公司对外投资取得一心堂国控大 药房河南连锁有限公司控股权的议案》，同意全资子公司河南鸿翔一心堂药业有限公司（以下 简称"河南一心堂"）对外投资取得一心堂国控大药房河南连锁有限公司（以下简称"一心堂 国控"）控股权。其中：河南一心堂以自有资金5,586.63万元受让北京九瑞天诚科技有限公司 持有的 ...

符合预期，区域渗透持续加 [Table_Title] 一心堂（002727.SZ） [Table_Summary] 核心观点： 2023 年销售收入 8.76 亿元；（2）泛健康业务：以健康美妆/个护/日化、 食品/奶粉为主的泛健康品类 2023 年实现销售 3.7 亿；（3）公益彩票 23 年销售流水 7698 万元；（4）中药产业完成云南三七、天麻等十大名药 产业链布局；（5）重点打造慢病专业门店，开展专业慢病管理服务等。 ⚫ 风险提示。竞争格局恶化；集采等政策风险；处方外流进展不达预期。 识别风险，发现价值 请务必阅读末页的免责声明 1 / 6 | --- | --- | |----------------------------|------------| | | | | [ 公司评级 Table_Invest] | 买入 | | 当前价格 | 21.08 元 | | 合理价值 | 25.64 元 | | 前次评级 | 买入 | | 报告日期 | 2024-05-05 | [分析师： Table_Author]罗佳荣 SAC 执证号：S0260523080002 liyatong@gf.com.cn ...

| --- | --- | |-------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...